Tumor derived adiponectin induces immunosuppressive macrophages in upper tract urothelial carcinoma

Read full text
Authors: Shen Cheng-Huang, P. C. Chen, Chia-Bin Chang, Chih-Chia Chang, Meilin Wang, Lien-Ping Chou, Ya-Yan Lai, Ming-Yang Lee, Shu-Fen Wu
Cited by: 0
References: 44

Abstract

• M2-type macrophages and m-MDSCs were increased in the periphery of UTUC patients. • Tumor-infiltrating M2 macrophage negatively correlated with tumor-infiltrating T cells in UTUC. • Both the supernatant from the UTUC tumor and adiponectin induced M2-like macrophage expression, leading to the inhibition of CD4 and CD8 T cells. Upper tract urothelial carcinoma (UTUC) is a rare urologic cancer that is more aggressive and has a poorer survival rate compared to bladder cancer. Previously, we linked the UTUC derived factors with tumor-infiltrating immune cells. Macrophages are considered the most abundant immune cell population within tumors and serve as key regulators of the tumor microenvironment. This study aimed to investigate their role in modulating immunosuppression in UTUC tumors. Our results indicated that UTUC patients had higher proportion of M2-type macrophages in the periphery, and that tumor-infiltrating M2 macrophages were inversely correlated with tumor-infiltrating T lymphocytes within UTUC tumors. The supernatants from UTUC tumor tissue, as well as the predominant factor adiponectin, caused upregulation of arginase-1 and CD206 expression in THP-1 differentiated macrophages. Furthermore, macrophages treated with supernatants from UTUC tumor tissue or adiponectin alone inhibited CD4 T cell and CD8 T cell proliferation, along with reduction of effective cytokines produced by T cells. These results suggest that macrophages modulated by adiponectin are associated with T cell suppression in the UTUC tumor microenvironment, highlighting a potential therapeutic target.

Fields of Study & Subjects

Adipokines Inflammation and Metabolic Diseases Immune cells in cancer IL-33 ST2 and ILC Pathways

Publication details

Journal / source
Translational Oncology
Volume
64
Pages
102599–102599
Publication date
6 January 2026
Language
EN